STARK

Drone Intelligence Assessment

STARK is the most heavily capitalised autonomous strike company Europe has produced, and it reached that position at unusual speed. Founded in Berlin in 2024, the company closed a €500 million Series C on 23 June 2026 at a valuation above €3.5 billion, co-led by Sequoia Capital and Founders Fund with participation from the NATO Innovation Fund, taking cumulative funding to roughly €640 million. The investor composition is the strategically distinctive feature. Sequoia and Founders Fund are foundational backers of Anduril Industries, the US autonomous strike company they have financed across successive rounds. Their co-investment alongside the NATO Innovation Fund in a direct European competitor points to a deliberate effort to seed a Western autonomous strike tier that spans national industrial bases rather than concentrating it in the United States.

Unlike most venture-stage defence companies, STARK arrives with a commercial architecture already in place. Its Virtus loitering munition, which ranges beyond 130 kilometres with endurance up to 90 minutes, underpins a €269 million Bundeswehr order announced in February 2026 to equip a German armoured brigade forward-deployed in Lithuania, STARK's share of a ~€540 million package split with Helsing following a Bundestag budget committee vote. The two systems unveiled in June 2026, the tube-launched Cascade at 40 to 100 kilometres and the man-portable Gambit at up to 25 kilometres, give STARK a three-tier product stack spanning long-range, medium-range, and organic battalion-level strike. That configuration mirrors the portfolio breadth of the leading US primes and reduces the risk of displacement by a single-capability specialist in a later procurement cycle.

The binding constraints are manufacturing and proven performance, not capital. More than 80 percent of the Series C is directed toward production as the company targets output measured in thousands of systems per month, a scale it has not yet demonstrated, against a Bundeswehr delivery commitment that leaves little schedule slack. Performance is the less-discussed risk, with reporting in mid-2026 raising questions about trial results even as the company and warhead specialist TDW point to a successful live-warhead test in the same period. The watch item over the next 12 to 18 months is whether Virtus clears Bundeswehr acceptance on schedule and whether STARK converts its allied backing into a second NATO sovereign contract before the European procurement cycle consolidates around established programmes.